Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 10, 2026 | June 12, 2026 |
| Crestline Lending Solutions, LLCN/A · Entity 23749 | Chief Operating Officer | July 24, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2036-06-10 | Direct | 50,500 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 50,500 · Balance 50,500 F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 99,486 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 99,486 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date.
Crestline Lending Solutions, LLC
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Limited Liability Company UnitsSEC Table I · non-derivative | Direct | 7,643.117 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Purchase · Acquired 7,643.117 · Balance 7,643.117 F1: Represents a purchase of securities from Crestline Lending Solutions, LLC (the "Company") in the form of a capital call. Under the terms of a subscription agreement between the reporting person and the Company, the reporting person is required to fund drawdowns to purchase the Company's units of limited liability interests up to the amount of their capital commitment with a minimum of ten business days' prior notice to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a purchase of securities from Crestline Lending Solutions, LLC (the "Company") in the form of a capital call. Under the terms of a subscription agreement between the reporting person and the Company, the reporting person is required to fund drawdowns to purchase the Company's units of limited liability interests up to the amount of their capital commitment with a minimum of ten business days' prior notice to the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 28, 2026 20:06 UTC | Crestline Lending Solutions, LLC N/A · Entity 23749 | PurchaseLimited Liability Company Units | 7,643.117 | $19.63 | $150,034.39 |
DisclosureSEC source: 0001628280-26-050148 · wk-form4_1785269180.xml · nonDerivative · entry 1 Cochran John · CIK 0001406773 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,643.117 F1 · shares: Represents a purchase of securities from Crestline Lending Solutions, LLC (the "Company") in the form of a capital call. Under the terms of a subscription agreement between the reporting person and the Company, the reporting person is required to fund drawdowns to purchase the Company's units of limited liability interests up to the amount of their capital commitment with a minimum of ten business days' prior notice to the reporting person. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 15:42 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 50,500 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001214659-26-007396 · marketforms-73382.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 50,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 17:58 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 42,000 | $3.41 Strike: $3.41 | $143,220.00 |
DisclosureSEC source: 0001214659-25-009120 · marketforms-69480.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 20, 2025, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 17:50 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 38,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001214659-24-011217 · marketforms-66324.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 20, 2025, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 25,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001214659-23-008793 · marketforms-61959.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 21, 2024, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 25,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001214659-22-008294 · marketforms-56515.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 22:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 20,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001214659-21-006719 · marketforms-53147.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| May 10, 2021 Filed Jun 1, 2021 20:11 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GiftCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-006162 · marketforms-52778.xml · nonDerivative · entry 1 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,486 F1 · kind: The reporting person gifted these shares of Common Stock to Event Facilities Fort Worth Inc. for no consideration. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:20 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherCommon Stock | 19,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003204 · marketforms-51914.xml · nonDerivative · entry 4 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,986 F1 · kind: Pro rata distributions for no consideration of shares of common stock of the Issuer by the following entities, respectively (collectively, the "Distributing Entities"): MonoLine Rx, L.P., MonoLine Rx III, L.P., MonoSol Rx Genpar, L.P., and MRX Partners, LLC. The Reporting Person under this Form 4 possesses no voting or investment control over the securities held by the Distributing Entities. Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:20 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherCommon Stock | 11,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003204 · marketforms-51914.xml · nonDerivative · entry 3 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,895 F1 · kind: Pro rata distributions for no consideration of shares of common stock of the Issuer by the following entities, respectively (collectively, the "Distributing Entities"): MonoLine Rx, L.P., MonoLine Rx III, L.P., MonoSol Rx Genpar, L.P., and MRX Partners, LLC. The Reporting Person under this Form 4 possesses no voting or investment control over the securities held by the Distributing Entities. Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:20 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherCommon Stock | 8,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003204 · marketforms-51914.xml · nonDerivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,351 F1 · kind: Pro rata distributions for no consideration of shares of common stock of the Issuer by the following entities, respectively (collectively, the "Distributing Entities"): MonoLine Rx, L.P., MonoLine Rx III, L.P., MonoSol Rx Genpar, L.P., and MRX Partners, LLC. The Reporting Person under this Form 4 possesses no voting or investment control over the securities held by the Distributing Entities. Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:20 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherCommon Stock | 23,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003204 · marketforms-51914.xml · nonDerivative · entry 1 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,123 F1 · kind: Pro rata distributions for no consideration of shares of common stock of the Issuer by the following entities, respectively (collectively, the "Distributing Entities"): MonoLine Rx, L.P., MonoLine Rx III, L.P., MonoSol Rx Genpar, L.P., and MRX Partners, LLC. The Reporting Person under this Form 4 possesses no voting or investment control over the securities held by the Distributing Entities. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 14,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-20-005755 · marketforms-49052.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 16, 2021, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 13,350 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001214659-19-004246 · marketforms-45221.xml · derivative · entry 2 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,350 Underlying: Common Stock · 13,350 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 13, 2020, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| July 24, 2018 Filed Jul 27, 2018 01:11 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 26,700 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033742 · form4.xml · derivative · entry 1 Cochran John · CIK 0001406773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.